Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.68 -1.1%	$9.57	$4.88 ▼ $19.58	$256.23M	N/A	101,250 shs	25,480 shs
CADL Candel Therapeutics	$5.86 -3.0%	$5.14	$3.79 ▼ $14.60	$302.62M	-0.87	1.45 million shs	710,793 shs
CGC Canopy Growth	$1.62 -4.7%	$1.33	$0.77 ▼ $8.65	$297.86M	0.75	5.93 million shs	10.88 million shs
KPTI Karyopharm Therapeutics	$4.21 -6.2%	$5.05	$3.51 ▼ $17.40	$36.37M	0.23	81,544 shs	59,574 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-1.10%	+4.94%	+12.09%	+12.09%	+1,167,999,900.00%
CADL Candel Therapeutics	-2.98%	+4.83%	+22.08%	-26.84%	-18.04%
CGC Canopy Growth	-4.71%	+33.88%	+22.73%	+47.27%	-76.96%
KPTI Karyopharm Therapeutics	-6.24%	+2.18%	-29.95%	-43.41%	-70.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	2.2811 of 5 stars	3.5	1.0	0.0	0.0	3.3	1.7	0.6
CGC Canopy Growth	1.5164 of 5 stars	1.5	2.0	0.0	0.0	2.4	0.0	1.3
KPTI Karyopharm Therapeutics	3.4898 of 5 stars	3.5	0.0	0.0	4.6	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	167.55% Upside
CADL Candel Therapeutics	3.00	Buy	$21.00	258.36% Upside
CGC Canopy Growth	1.00	Sell	$2.00	23.46% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	926.13% Upside

Current Analyst Ratings Breakdown

Latest KPTI, CADL, CGC, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/15/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/1/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
3/27/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
3/14/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/10/2025	AARD Aardvark Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$29.00

(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	$120K	2,446.70	N/A	N/A	$0.44 per share	13.32
CGC Canopy Growth	$269.00M	1.11	N/A	N/A	$2.72 per share	0.60
KPTI Karyopharm Therapeutics	$142.13M	0.26	N/A	N/A	($1.47) per share	-2.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	-$37.94M	-$1.34	N/A	N/A	N/A	N/A	-629.29%	-173.39%	8/12/2025 (Estimated)
CGC Canopy Growth	-$487.23M	-$4.04	N/A	N/A	N/A	-156.98%	-56.52%	-24.18%	8/8/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)

Latest KPTI, CADL, CGC, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	1.18	1.18
CGC Canopy Growth	0.74	3.52	2.58
KPTI Karyopharm Therapeutics	N/A	1.70	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
CADL Candel Therapeutics	13.93%
CGC Canopy Growth	3.33%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
CADL Candel Therapeutics	16.60%
CGC Canopy Growth	1.30%
KPTI Karyopharm Therapeutics	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
CADL Candel Therapeutics	60	50.10 million	18.97 million	Optionable
CGC Canopy Growth	3,150	183.87 million	153.39 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable

KPTI, CADL, CGC, and AARD Headlines

Recent News About These Companies

Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $43.20

June 10 at 1:59 AM | americanbankingnews.com

Karyopharm to Present at the Jefferies Global Healthcare Conference

June 3, 2025 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | prnewswire.com

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

May 26, 2025 | zacks.com

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

May 19, 2025 | zacks.com

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025 | prnewswire.com

Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

May 15, 2025 | marketbeat.com

Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Estimates By $1.44 EPS

May 14, 2025 | marketbeat.com

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025 | prnewswire.com

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025 | prnewswire.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%

May 6, 2025 | aaii.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | prnewswire.com

Karyopharm Therapeutics Inc.DL-Exch. Notes 2018(25) Bond

May 1, 2025 | markets.businessinsider.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 5.06%

April 30, 2025 | aaii.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | prnewswire.com

Karyopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler

March 20, 2025 | markets.businessinsider.com

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, CADL, CGC, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.68 -0.13 (-1.10%)

As of 06/9/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Candel Therapeutics NASDAQ:CADL

$5.86 -0.18 (-2.98%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$5.94 +0.08 (+1.37%)

As of 06:15 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Canopy Growth NASDAQ:CGC

$1.62 -0.08 (-4.71%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$1.60 -0.02 (-1.23%)

As of 06:16 AM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Karyopharm Therapeutics NASDAQ:KPTI

$4.21 -0.28 (-6.24%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$4.33 +0.12 (+2.85%)

As of 05:23 AM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time